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ABSTRACT   
 
Objective 
This  UK-wide OATech+ Network consensus  study utilised a Delphi approach to discern levels  
of awareness across an expert panel regarding the role of existing and novel technologies  in 
osteoarthritis research. To direct future cross-disciplinary research it aimed to identify which could 
be adopted to subcategorise patients with osteoarthritis (OA).   Design  
An online questionnaire was formulated based on technologies which might aid OA research and 
subcategorisation.  During a two-day face-to-face meeting concordance of expert opinion was 
established with surveys (23 questions) before,  during and at the end of  the meeting (Rounds 1,2 
and 3, respectively). Experts spoke on current evidence for imaging, genomics, epigenomics, 
proteomics, metabolomics, biomarkers, activity monitoring, clinical engineering and machine 
learning relating to subcategorisation.   For each round of voting, ≥80% votes led to consensus and 
≤20% to exclusion of a statement. 
Results 
Panel members were unanimous that a combination of novel technological advances have potential 
to improve OA diagnostics and treatment through subcategorisation,. agreeing in Rounds 1 and 2 
that epigenetics, genetics, MRI, proteomics, wet biomarkers and machine learning could aid 
subcategorisation. Expert presentations changed participants’ opinions on the value of 
metabolomics, activity monitoring and clinical engineering, all reaching consensus in Round 2.   X-
rays lost consensus between Rounds 1 and 2; clinical X-rays   reached consensus in Round 3.  
Conclusion 
Consensus identified that 9 of the 11 technologies should be targeted towards OA subcategorisation 
to address existing OA research technology and knowledge gaps. These novel, rapidly evolving 
technologies are recommended as a focus for  emergent, cross-disciplinary osteoarthritis research 
programmes.  
Keywords (4-6 words). 
Stratification; Osteoarthritis; Technology;  Phenotype; Omics; Biomarkers. 
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INTRODUCTION 1 
 2 
It is predicted that there will be a 4- to 6-fold increase in the number of total joint replacements 3 
for osteoarthritis (OA) in the coming decades
[1]
.  Despite the increase in prevalence and the large 4 
body of literature existing on the subject, definitions of OA subgcategories, whether in clinical or 5 
research environments, are often disparate.  The OATech Network+, a multidisciplinary 6 
consortium, had identified this as a potential limitation to furthering OA research. Whilst X-rays 7 
are one of the most commonly used technologies for studying OA for decades, there have been 8 
many recent technological developments applied to the field, for example, in genomics and other 9 
‘omics’, different forms of imaging, and computational analysis of big data.  10 
 11 
The OATech Network+ organised a consensus meeting combining experts in a broad range of 12 
existing and novel technologies (with basic scientists and clinicians) to appraise the potential of 13 
existing and new technologies and improve OA subcategorisation. A Delphi approach was 14 
adopted, aiming to recommend improved  targeting of technology for OA subcategorisation  so 15 
that existing and emerging treatments could be applied more effectively to selected patients or 16 
subgroups.   17 
 18 
The meeting commenced with experts in the fields of engineering, rheumatology, orthopaedic 19 
surgery, radiology, physiotherapy, biology and OA pain perception sharing their experience of 20 
OA research. Experts in more recently developed technologies lectured on their OA research 21 
application, summarised below. 22 
 23 
Genetics and genomics  24 
 25 
The field of complex trait genetics has witnessed a revolution in technological advances over the 26 
last decade, enabling the genome-wide interrogation of sequence variation, leading to the 27 
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discovery of thousands of genetic risk loci. Recent methodological advances have also enabled 28 
deep molecular characterisation of disease-relevant tissues collected from human patients or 29 
studied in cellular and organismal models of disease. Together, these can help enhance our 30 
understanding of the mechanisms underlying disease development and progression
[2]
. Large-31 
scale genetics can help improve our understanding of the genetic aetiology of OA and related 32 
sub-groups by interrogating big data in genetics, genomics and medically-relevant phenotypes 33 
from rich epidemiological resources, patient collections and disease registries. Functional 34 
genomic approaches for integrated molecular phenotyping of relevant cell types can help 35 
translate insights from genomics into mechanisms of disease in order to overcome the critical 36 
barrier of there being currently no disease-modifying treatment for OA. The relevant diseased OA 37 
tissues are readily available from joint replacement surgery, enabling the study of molecular 38 
processes in the appropriate tissues, both to fill a gap in our fundamental understanding of 39 
biology and to identify novel therapeutic avenues. 40 
 41 
Epigenetics and Functional Analysis 42 
 43 
Epigenetics is a mechanism used by the cell, tissue and organ to regulate gene expression in a 44 
dynamic manner by reversible chemical changes to the genome. There are three epigenetic 45 
markers: DNA methylation, histone modification and the activity of regulatory RNAs
[3]
. Epigenetic 46 
changes are context specific and show temporal and spatial effects. They act during 47 
skeletogenesis and joint formation, and have a role in OA
[3-5]
. As for genomic studies, the 48 
diseased joint tissues such as articular cartilage, synovium or bone, are used in relatively large 49 
quantities to extract DNA, chromatin and RNA for epigenetic analysis. Such studies have led to 50 
subcategorisation of OA by, for example, identifying individuals who appear to have an 51 
inflammatory component to their disease
 [4]
.  52 
 53 
Proteomics and Metabolomics 54 
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 55 
Proteomics and metabolomics can be used to identify molecules as possible predictors of early 56 
disease, disease progression and response to treatment.  Synovial fluid contains systemic 57 
proteins and metabolite markers of disease and holds significant potential for the discovery of 58 
proteins and metabolites to aid subcategorisation of the disease. 59 
 60 
Whilst transcriptomics can indicate the proteome, the relationship between mRNA and proteins 61 
is complex and thus identifying proteins in a sample and how they vary is paramount. 62 
Quantitative proteomic differences between sample groups can be identified using either 63 
absolute or relative quantification, with or without labelling (reviewed
[6]
). Absolute quantification 64 
has been used to measure up to 20 targeted proteins in a single experiment
[7]
. Label-free relative 65 
quantification using synovial fluid has been used and predictors of treatment outcome with 66 
autologous chondrocyte implantation (ACI) have been investigated for a number of biomarkers
[8]
.  67 
Nuclear magnetic resonance (NMR) and MS have been used in assessing metabalomics, being 68 
non-destructive, quantitative, reproducible and cost effective.  Both techniques have identified 69 
up to 32 differentially expressed metabolites in synovial fluid from OA and rheumatoid arthritis
[9].
 70 
 71 
Degradomics is another proteomic method that may be useful in OA subcategorisation, assessing 72 
cleavage products at different stages in OA
[8]
. A further development, Matrix Assisted Laser 73 
Desorption Ionization Mass Spectrometry Imaging (MALDI-IMS), has been used to identify 74 
proteins and neopeptides altered in cartilage ageing and OA
[8]
.  75 
 76 
Molecular signatures and biomarkers 77 
 78 
All the above techniques (genomics, epigenomics, proteomics) can assist in the search for OA 79 
biomarkers , in terms of the “Burden of disease, Investigative, Prognostic, Efficacy of intervention 80 
and Diagnostic (BIPED)” classification scheme
[10]
. To date, many candidate proteins, 81 
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carbohydrates and lipids
[11]
 have been investigated
[12]
. Several are associated with disease 82 
progression in OA cohorts, but are not able to stratify individuals
[13]
. A ‘molecular signature’ 83 
representing multiple protein or non-protein markers may be more realistic for OA than finding a 84 
single biomarker, perhaps better indicating relevant shared mechanisms within the disease.  85 
 86 
Although singleplex antibody-based assays remain the mainstay for investigation of candidate 87 
protein biomarkers, multiplexing with higher sensitivity and specificity for complex biological 88 
fluids is now possible by proprietary adaptive immunoassay approaches, such as 89 
electrochemiluminescence or proximity extension assays (combining antibody and PCR 90 
technology)
[14]
. Whether using immunoassay or mass cytometry (e.g. CyTOF), antibodies limit the 91 
absolute number and combinations possible, whereas non-antibody approaches circumvent 92 
these issues. Modified aptameric assays (aptamers being short sequences of nucleotides which 93 
are selected for their specificity to bind proteins in much the same way as an antibody) can be 94 
multiplexed to quantify thousands of proteins simultaneously in a single sample. These 95 
approaches have the ability to identify molecular endotypes (molecular subgroups in disease) or 96 
to predict drug toxicity and transform the way we are able to dissect molecular pathways or 97 
identify molecular signatures as biomarkers in biological fluids.  98 
 99 
Clinical Engineering 100 
 101 
The International Classification of Functioning, Disability and Health (ICF) provides a framework 102 
for understanding disability which links the body functions and structures to activity and 103 
participation.  Clinical movement analysis, in particular 3D gait analysis, allows clinicians to 104 
measure the impact of OA on walking.  This is important as patients often perceive their walking 105 
pattern as a cause as well as a consequence of the disease.  Patients with unilateral disease often 106 
develop bilateral symptoms
[15]
. 107 
 108 
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Previous work
[16]
 has described gait in patients with single joint disease, who do not have a 109 
typically antalgic gait pattern, but have knee loading which is high throughout the stance phase, 110 
giving them a high moment impulse, combined with muscular co-contraction.  This co-111 
contraction, measured using electromyography (EMG) further increases contact forces in the 112 
joint.  3D gait analysis can detect bilateral overloading in both hip and knee joints in patients with 113 
unilateral, single joint disease.  The adopted tentative gait pattern seems to predispose other 114 
joints to OA . 115 
 116 
Whilst knee pain and loading measures improve after knee arthroplasty, some patients improve 117 
more than others and abnormal loading patterns often persist
[16]
.  3D gait analysis is useful in 118 
understanding the control and loading of the joints during movement and interpreting how these 119 
change in OA gait is important in providing appropriate therapies, such as bracing or biofeedback. 120 
 121 
In knee OA populations biomechanical measures at baseline have also been used to predict 122 
radiographic disease progression
[17]
, future total knee arthroplasty (TKA)
[18]
 and stratify response 123 
to interventions such as and lateral wedge insoles and TKA
[16]
. 124 
 125 
Activity monitoring 126 
 127 
Recent OARSI guidelines have advocated the use of activity monitoring devices to collect 128 
objective measures of physical activity
[19]
.  It is important for individuals with OA to remain 129 
physically active. Evidence indicates that it can reduce OA related pain,  in addition to increasing 130 
muscle strength, joint range of motion and cardiovascular fitness
[20]
. Physical activity levels 131 
measured in OA populations over the longer term (3-12 months post-surgery) show no 132 
substantial increases in activity after 12 months
[21] 
. Therefore more behavioural interventions are 133 
required to promote physical activity in the recovery period; a conclusion that could be missed 134 
when using more subjective self-reported measures.  135 
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 136 
Activity monitoring technology is rapidly advancing but for subgrouping of OA requires large 137 
amounts of data.  Smart phones and wearable technology now offer the potential to collect this 138 
data outside of the laboratory and unobtrusively.     139 
 140 
Machine Learning and ‘Big Data’  141 
 142 
Much of the technology described with potential to improve OA stratification creates very large 143 
data sets which require computational analysis; as the quantity of data increases, meaningful 144 
analysis becomes more challenging.  The use of complex artificial neural network architectures 145 
or machine learning (ML) have been shown to be capable of representing and learning 146 
predictable relationships in many diverse types of data.  These computational tools hold promise 147 
for transforming the future of ‘omics’ and other technologies which acquire huge data sets or 148 
Big Data
[22]
. 149 
 150 
Imaging modalities such as MRI are used as clinical diagnostic tools and contain vast amounts of 151 
information which lend themselves well to analysis via ML. In the following example, ML is 152 
applied to image analysis of OA in the spine, thus demonstrating the potential value of this 153 
technology in identifying subgroups of OA. ML has been used to develop an automated method 154 
for grading degeneration in the spine and intervertebral disc on MRIs
[23, 24]
,  as used in the 155 
Pfirrmann Score
[25] 
for degenerative disc disease or OA of the spine (developed as ‘SpineNet’). 156 
The system can robustly extract measurements for this, in addition to having the potential to 157 
identify other phenotypes such as spinal stenosis or ‘Modic’ changes in the vertebral endplates. 158 
This approach requires well defined cohorts of patients with appropriate levels of consent for 159 
this type of data storage and analysis, both for developing the program and then subsequently 160 
independent cohort(s) for validation. SpineNet also has the capability of producing so-called 161 
‘Hotspots’ or saliency images that can be used to visualize the parts of the MRI that are the likely 162 
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source of the output
[23]
, so possibly defining completely new phenotypes from this unbiased 163 
approach.  164 
 165 
A prerequisite for imaging biomarker discovery is the extraction of robust and discriminative 166 
radiological measurements from joint MRIs; however, the lack of imaging biomarker 167 
standardisation within the research community, the inherent intra- and inter-reader variability 168 
and time and cost has hampered research to date.  Clearly ML is providing a powerful tool to aid 169 
in the analysis of ‘big data’ and medical images with diverse applications too numerous to 170 
discuss here. Future ML, computational analysis and the development of automated programs, 171 
can offer robust, repeatable and rapid analysis of large datasets (MRI images or any other 172 
potential ‘biomarker’, provide important tools for subcategorization and identification of OA 173 
biomarkers . As novel markers of OA emerge across the biological, biomechanical, clinical and 174 
imaging interfaces, their combination will provide increasingly powerful datasets and 175 
opportunities for ML applications across OA diagnostics and classification domains.    176 
 177 
In summary, the technologies mentioned above have developed rapidly in the last decade.  For 178 
example, a literature search for ‘genomics’ or ‘epigenomics’ (using Medline and Embase) over 179 
the last 30 years highlights the increased awareness and use of such technology. From 1990-180 
1999 genomics or epigenomics shows a total of 10 publications, 2000-2009 shows 7,322 and 181 
2010-2019 shows 23,426.  With the continuous evolution of these technologies, it seemed 182 
appropriate that the OATech Network+ should address the topic of the potential of technologies 183 
for subcategorising OA and it was felt that a Delphi meeting would be an appropriate approach.  184 
 185 
METHODS 186 
 187 
This Delphi study consisted of a two-day focus group meeting (see programme in Supplementary 188 
Table 1),  together with online surveys using ‘Google Forms’, to assess the level of agreement on 189 
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a number of statements relating to OA and the use of different technologies (see Supplementary 190 
Table 2). The group consisted of a number of different specialists (listed in Table 2), all with 191 
expertise and significant interest in OA (Supplementary Table 3).  A questionnaire was 192 
formulated based on the most widely used technologies and research tools which may aid 193 
subcategorisation of OA. The technologies were chosen by the organisers from their knowledge 194 
of the field and review of the literature, including a search performed for this study.  Selected 195 
examples of OA categorisations were taken from the recent literature through primary searches 196 
(using Medline, EMBASE and PubMed with ‘definition of osteoarthritis’ as a search term) and 197 
articles known to the authors. Questions requiring free-text opinions of panel members were 198 
included in the questionnaire, for example, ‘were any questions missing’ and ‘what was their 199 
personal definition of OA?’. Answers to the latter were used to start discussions at the meeting 200 
and to assess the similarity of expert definition and understanding of OA. Expert consensus was 201 
reached for each statement when ≥80% participants agreed with the statement and rejected if 202 
≤20% of participants agreed, as commonly used in previous Delphi studies
[26]
.  203 
 204 
The questionnaire was tested on 3 world leading experts in the field of OA (Professors Richard 205 
Loeser, Mary Goldring and Virginia Kraus) and modified slightly on their advice, before being 206 
sent to the Delphi panel electronically.  Panel members were asked if they agreed/disagreed 207 
with each of the statements. Round 1 was completed before the two day meeting. Talks were 208 
given at the start of the meeting by experts in the technologies presented in the Introduction. All 209 
statements in Round 1 were retained for Round 2, viewed ‘live’ on the Delphi on Google Form; 210 
any questions/statements which did not reach consensus in Round 2 were discussed in fine 211 
detail with participants suggesting potential improvements to statements. Once unanimous 212 
agreement on the wording was achieved, the wording was altered in the survey for voting on in 213 
Round 3 at the end of day 2. These changes to wording are shown in Table 1. 214 
         Please insert Table 1 here  215 
 216 
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 217 
The aims of the Delphi study were to determine, using a panel of experts, 1. whether novel and 218 
existing technologies could aid in the subcategorisation of patients with osteoarthritis (OA) and 219 
2. whether there is good knowledge and awareness of these technologies. This could then help 220 
define what technology gaps exist to allow recommendations on the focus of future 221 
collaborative and cross disciplinary research. 222 
 223 
Participant identification and inclusion 224 
 225 
Experts were selected from a wide range of disciplines relevant to the field of OA.  All 130 226 
members of the OATech Network+ were invited to take part.  The Delphi questionnaire was 227 
emailed to 36 potential Delphi panel experts, who were all active in the OA field and expressed 228 
an interest in attending the meeting.   The minimum requirement for all invited experts was to 229 
complete all three rounds of the Delphi and attend the meeting.  230 
 231 
RESULTS  232 
 233 
Thirty three experts responded and completed the Round 1 questionnaires and attended the 234 
meeting, so becoming the Delphi panel (Supplementary Table 3). This consisted of basic science 235 
researchers, orthopaedic surgeons, physiotherapists, rheumatologists, engineers, radiologists, 236 
veterinary researcher and a clinical efficacy researcher from the UK (n=31), America (n=1) and 237 
the Netherlands (n=1).  However, several members were multi-faceted, e.g. being clinically 238 
active and performing basic research and running clinical trials. The questionnaire showed 37% 239 
of the panel members were actively treating patients whilst 63% were not, but might have 240 
patient contact.  Twenty seven percent of panel members had been working in the field of OA 241 
for 0-5 years, with 24% being involved for >20 years (Supplementary Figure 1). Although the 242 
Delphi panel was made up of a diverse group of experts, none were experts in Delphi 243 
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methodology. However, several panel members had significant, relevant experience of the 244 
process to mitigate this limitation. 245 
          246 
The wording in the statements and the results of the Delphi questionnaire over 3 rounds are 247 
shown in Table 1 and summaries of the definitions of OA provided by participants from different 248 
disciplines in Table 2. Not all panellists answered the question on defining OA as all questions 249 
were optional for panel members, so results are shown from those available, with only small 250 
variations between and within professions. 251 
                                         252 
None of the six categorisations of OA taken from recent literature reached consensus in any 253 
round (Table 1). Furthermore, 4 of the 6 literature-derived definitions demonstrated a decrease 254 
in agreement between Rounds 2 and 3 (following the face-to-face meeting).  255 
                Insert Table  2 here. 256 
In contrast, there was unanimous agreement in Rounds 1 & 2 that the latest technological 257 
advances could be used to improve OA subcategorisation (Table 1 & Figure 1). Of the 258 
technologies identified, only the statement ‘X-rays alone can be used to categorise OA 259 
phenotype’ failed to reach consensus in rounds 1 and 2, whilst there was no consensus in Round 260 
2 for either X-rays or ultrasound as technologies which would to improve clinical OA 261 
subcategorisation (Table 1). 262 
Insert Figure 1 here. 263 
The technologies which gained greatest consensus in Round 2 for being of use in improving 264 
subcategorisation of OA were: ML (100%), genetic analysis and MRI (both 97%), proteomics and 265 
wet biomarker analysis (both 93.8%), activity monitoring (90.9%), metabolomics (both 90.6%), 266 
epigenomics and clinical engineering (both 88%).  Eighty three percent of participants thought X-267 
rays could aid subcategorisation of OA in Round 1, but this reduced to 49% in Round 2, whilst for 268 
ultrasound this changed from 59% in Round 1 to 67% in Round 2.  Ultrasound was described as 269 
useful for identifying inflammation in the knee and could therefore be valuable in 270 
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subcategorising OA, although some members did not feel that there was sufficient evidence 271 
presented to make an informed decision as this technology was not presented at the meeting. 272 
 273 
There was much discussion on the usefulness of X-rays and the commonly used Kellgren-274 
Lawrence (KL) score for staging disease.  Discussions highlighted that radiography is considered 275 
outdated and flawed, but that X-rays are still the gold standard (alongside clinical criteria) for 276 
diagnosis and assessing OA in the clinic, e.g. for suitability for arthroplasty.  277 
 278 
DISCUSSION 279 
 280 
Whilst OA has long been recognised as a heterogeneous multi-faceted disorder, progress into 281 
defining subgroups or categories has been poor; this is a likely reason why several clinical trials 282 
of novel pharmaceuticals or Disease Modifying Osteoarthritis Drugs (DMOADs) have failed
[27-29]
.  283 
In other areas of medicine such as asthma, subcategorisation has been achieved according to 284 
the pathological mechanisms (i.e. molecular endotyping) and clinical phenotyping
 [30]
.  It is to be 285 
hoped that this can be achieved for OA, resulting in improved diagnosis, understanding of 286 
disease mechanisms, identification of novel therapeutic targets, the development of new 287 
therapies and, subsequently better stratification and improved treatment of patients.  Indeed, 288 
this was a conclusion of the inaugural meeting of an EPSRC-funded UK initiative for the OATech 289 
Network+, with the subsequent decision to utilise a Delphi-style process to address this topic.   290 
 291 
As technology becomes more sophisticated and specialised there is a danger of working 292 
increasingly in silos.  This process, including expert participants (>20% having >20 years’ OA 293 
research experience), from several disciplines, facilitated an appraisal across key areas where 294 
technology has made great advances.  The benefits associated with this were indicated in 295 
participant feedback, for example, the change in consensus on technologies such as clinical 296 
engineering.  The process highlighted a consensus belief that adopting key existing and emerging 297 
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technologies (ML, genetic analysis, MRI, proteomics, wet biomarker analysis, activity monitoring, 298 
metabolomics, epigenomics and clinical engineering), would increase successful delivery of 299 
improved OA subcategorisation and discussions raised many suggestions as detailed below.  In 300 
contrast, existing literature provided little agreement on the approach to OA categorisations and 301 
indeed, other studies that have highlighted the urgent need for updated definitions and 302 
categories
[31,32]
. 303 
X-rays, discussed at length, are well known to have limitations, especially with regard to the KL 304 
scoring system for radiographic diagnosis of OA
[33,34]
.  The inclusion of clinical and non-clinical 305 
participants was particularly beneficial with orthopaedic surgeons highlighting that X-rays 306 
remain a valued clinical technology, being relatively simple, cheap, readily available and 307 
routinely and useful for diagnosis and treatment decisions.   The KL radiographic classification 308 
scheme for OA, first described in 1957
[33]
, remains the most widely used clinical tool for the 309 
radiographic diagnosis of OA
[34]
, despite its known limitations. Hence X-rays should be retained in 310 
OA studies and based on previous improvements
[35]
, the optimistic aim is to enhance their use 311 
through further application of ML and AI. 312 
 313 
Epigenetic changes can modulate the impact of risk-conferring alleles of DNA polymorphisms 314 
that are associated with OA. For example, if a polymorphism is in a gene-regulatory element and 315 
the risk allele reduces gene expression, its effect can be attenuated or aggravated by DNA 316 
methylation of that element in an allele-specific manner
[4]
. As such, subgrouping OA patients by 317 
their genetic and epigenetic profile might reduce the heterogeneity seen across patients and 318 
enhance the interpretability of functional studies of genetic risk.    319 
 320 
Large datasets generated from activity tracking through the increased adoption of smartphones 321 
and wearables, are likely to provide further opportunities to aid the stratification of OA 322 
populations. Activity monitoring research in OA populations has, in the past, been limited to 323 
measurements over short durations (i.e. up to 7-days), hence providing limited insight. Fitness 324 
13 
 
trackers and smart phones have revolutionised the opportunities to collect continuous activity 325 
data more reliably and over longer time periods. Objective measures of physical activity can be 326 
used for monitoring recovery e.g. following joint arthroplasty, to measure short term recovery in 327 
terms of daily step count change over the first four weeks post-surgery
[36]
. Extending this 328 
approach over a large sample population would allow an expected trajectory of recovery to be 329 
developed such that patients deviating from it could, for example, be flagged for follow-up 330 
consultation. Deeper analysis and modelling of the inertial sensor data collected by wearables 331 
will be important for categorising OA populations. For example, multi-dimensional analyses of 332 
activity data have been found to be more accurately associated with functional test outcomes 333 
than step-count and sedentary time measures alone
[37]
. Similarly, studies have investigated 334 
longer term monitoring with follow-up measures at 3-12 months post-surgery
[21]
. Interestingly, 335 
there was no substantial increases in activity after 12-months, concluding that more behavioural 336 
interventions are required to promote physical activity in the recovery period.  337 
 338 
ML was the only technology reaching 100% consensus in its ability to improve OA 339 
subcategorisation in Round 2 of the Delphi, highlighting recognition of its potential use .  During 340 
discussions, the importance of integrating data, especially ‘big’ data, across disciplines and the 341 
application of ML approaches was highlighted as being of great importance.  In big data science, 342 
ML is based on computer algorithms that can learn to identify complex patterns based on real 343 
data
[38, 39]
. The goal of ML is to enable an algorithm to learn from past and/or present data and 344 
then to make predictions or decisions for unknown future events
[40]
.  345 
 346 
ML/AI is of paramount importance to all technologies  generating ‘big data’, such as genomics, 347 
all omics and imaging modalities now used   in biomarker and molecular signature discovery in 348 
OA.  The use of ML/AI in integrating these advanced analytical techniques, , provides the 349 
opportunity to build and test complex models incorporating important non-biomarker 350 
covariates.  Multi-omics data has enabled biomarkers generations for the stratification of 351 
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patients into subgroups e.g. in oncology and other chronic diseases such as asthma
[41,42]
. This 352 
allows subcategorisation into groups based on genetic variability and other biomarkers so that 353 
medications may be tailored to individuals
[43, 44]
. Big data systems using multi-omics (genomics, 354 
proteomics, metabolomics and epigenomics), enables, understanding of interactions and 355 
functions of the genome, often identifying unexpected functions or possibly illustrating the 356 
interplay between the genome, the cellular environment and the progression of disease.   357 
 358 
In summary, a Delphi-type exercise was undertaken as a route to obtaining expert consensus 359 
from a range of disciplines, regarding the role of novel experimental technology in OA research. 360 
It provided a valid route to recommendations for the focus and direction that should be adopted 361 
by the cross-disciplinary OA research community.  Rather than employing individual 362 
technologies, it is likely that combining several identified technologies (eg proteomics, imaging 363 
and clinical engineering, together with machine learning), across sites, focussing on one or more 364 
OA subgroups will reap real benefits and provide important advances in the field of 365 
osteoarthritis research. 366 
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Figure legends 610 
Figure 1.A. Frequency histogram indicating change of panel members’ response as to whether 611 
different technologies were able to improve OA stratification in Round 1 (before the focus meeting) 612 
and Round 2 (after the instructive lectures at the start of the meeting). Nine of the 11 technologies 613 
reached consensus after the 2
nd
 round.  B. The modified question related to X-ray and ultrasound 614 
technologies for the 3
rd
 round for the clinic and research and the % agreement. 615 
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Table 1. Statements used in the DELPHI and the percentage of participants who agreed with the 654 
statements at each Round. 655 
 
 DELPHI statement/Question 
Round 1 Round 2 Modified question for 
round 3 
Round 3 
Percentage agreement with statement 
 
1 OA is a disease of  
i. Bone  
ii. Cartilage  
iii. Bone and cartilage 
 
1. 2.9 
2. 5.7 
3. 91.4 
 
1. 3.1 
2. 0 
3. 96.9 
  
2 OA always involves other tissues in 
the joint in addition to bone and or 
cartilage 
63.9 87.9 OA involves other tissues 
in the joint in addition to 
bone and cartilage 
100 
3 Early OA needs categorising 
differently to ‘established OA 
86.1 87.9 Panel decided not to take 
this question forward 
 
4 Osteoarthritis needs re-defining 65.7 69.7   
5 OA is a continuum 88.6 97   
6 Subcategorising OA is useful 94.3 100   
7 The definition of OA needs to be 
joint specific 
55.6 69.7 The definition of OA needs 
to encompass joint 
specific differences 
66.7 
8 OA phenotypes should rely on 
underlying mechanisms 
73.5 84.8   
9 X-rays alone can be used to 
categorise OA phenotype 
5.6 6.1   
10 The Kellgren-Lawrence (KL) is the 
most appropriate for categorising OA 
on X-ray 
50 74.2 There is a need for an 
improved scoring system 
than the Kellgren-
Lawrence for X-rays 
93.9 
11 MRI has no role to play in 
categorising OA 
2.8 9.1   
12 A universal OA categorisation system 
can be used for all clinical cases of 
OA 
44.4 56.3 Panel decided not to take 
this question forward 
 
13 The same categorisation system for 
OA can be used in the clinic and or 
research studies 
57.1 59.4 The same categorisation 
system for OA should be 
used in the clinic and or 
research studies 
78.8 
14 The latest technological advances 
can be used to improve OA 
subcategorisation 
100 100   
15 Please say if you agree or disagree 
that the application of the following 
technologies can improve clinical OA 
subcategorisation 
Epigenomics 
Genetic analysis 
MRI 
X-ray 
Ultrasound 
Metabolomics 
Proteomics 
Wet biomarker analysis 
Machine learning (AI) 
Activity monitoring 
Clinical engineering 
 
 
 
 
 
84.8 
91.4 
100 
82.9 
58.8 
78.8 
87.9 
97.1 
88.9 
68.6 
72.2 
 
 
 
 
87.5 
97 
97 
48.5 
66.7 
90.6 
93.8 
93.8 
100 
90.9 
87.5 
 Clinical 
 
 
 
 
 
 
87.9 
75.8 
Research 
 
 
 
 
 
 
75.8 
69.7 
22 
 
16 Different OA subcategorisation 
systems have been suggested in the 
literature recently.  Please say if you 
agree or disagree with the following 
statements taken from the literature. 
A. Examples of OA can be: 
Hip/knee/hip and or knee
[45]
 
 
B. Pain, symptoms, clinical 
examination and X-rays are 
the most useful factors in 
diagnosing early OA
[46]
 
 
C. Pain, psychological distress, 
radiographic severity, BMI, 
muscle strength, 
inflammation and 
comorbidities are all 
associated with clinically 
distinct OA phenotypes
[47]
 
 
D. Minimal joint disease, 
malaligned, biochemical, 
chronic pain, inflammatory 
metabolic syndrome and 
bone and cartilage 
metabolism are all main 
phenotypes of OA
[48]
 
 
E. Knee OA phenotype is 
defined by patient reported 
frequent knee pain, 
cartilage damage and the 
presence of degenerative 
meniscal tissue
[49]
 
 
F. OA can be classified by 
symptomatic radiographic 
OA (primary criteria) and 
pain alone (secondary 
criterion). 
 
 
 
 
 
 
 
58.3 
 
 
45.7 
 
 
 
 
60 
 
 
 
 
 
 
 
61.8 
 
 
 
 
 
 
 
58.8 
 
 
 
 
 
 
31.4 
 
 
 
 
 
 
 
 
 
 
72.7 
 
 
36.4 
 
 
 
 
69.7 
 
 
 
 
 
 
 
72.7 
 
 
 
 
 
 
 
48.5 
 
 
 
 
 
 
24.2 
  
 
 
 
 
51.5 
 
 
42.4 
 
 
 
 
51.5 
 
 
 
 
 
 
 
48.5 
 
 
 
 
 
 
 
39.4 
 
 
 
 
 
 
36.4 
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Table 2.  Definitions of OA from different professions on the Delphi panel. 671 
Profession OA definition 
Physiotherapists A syndrome affecting the joints of the body 
Joint pathology leading to pain and functional limitation that involves 
genetics and epigenetic factors 
Rheumatologists Structural alteration of cartilage and bone in a joint which results in 
pain and loss of function 
A disease of the whole joint with distinct clinical and structural 
phenotypes 
A disease of many tissues of the joint including cartilage and bone, 
associated with pain or stiffness 
Osteoarthritis is a whole-joint disease, affecting articular and 
periarticular tissues.  It has components of degeneration, 
regeneration and low-grade inflammation that differ in extent and 
clinical consequences between joints, disease stages and patients 
Orthopaedic Surgeons Structural and biological derangement of joint (that isn’t 
rheumatoid/ankylosing spondylosis/psoriatic 
A painful condition involving changes in multiple tissues of the joint 
Engineers A disease of the joint, characterised by pain, loss of function and 
degeneration/progressive damage of structures in/around the joint 
Musculoskeletal disease possibly triggered by altered joint 
biomechanics and biological signalling leading to joint tissue 
degeneration, inflammation and pain 
Radiologist Degenerative joint change currently based on exclusion of other 
causes 
Vet Degenerative whole joint disease with an inflammatory component 
Scientists (researcher) Joint disease that results in cartilage degeneration, bone changes and 
pain 
Degenerative disorder of the joint 
A degenerative disease of the bone and cartilage.  Can lead to 
cartilage loss, joint inflammation, changes in the bone and pain 
* The number of comments shown indicates the number of people who provided definitions in each 672 
profession. 673 
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Figure 1. 694 
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